KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Asset Writedowns and Impairment: 2011-2024

Historic Asset Writedowns and Impairment for TherapeuticsMD (TXMD) over the last 12 years, with Dec 2024 value amounting to $1.3 million.

  • TherapeuticsMD's Asset Writedowns and Impairment was N/A to $7,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $608,000, marking a year-over-year change of. This contributed to the annual value of $1.3 million for FY2024, which is N/A change from last year.
  • Latest data reveals that TherapeuticsMD reported Asset Writedowns and Impairment of $1.3 million as of FY2024, which was up 137.90% from $533,000 recorded in FY2021.
  • TherapeuticsMD's Asset Writedowns and Impairment's 5-year high stood at $1.3 million during FY2024, with a 5-year trough of $533,000 in FY2021.
  • Moreover, its 1-year median value for Asset Writedowns and Impairment was $1.3 million (2024), whereas its average is $1.3 million.
  • As far as peak fluctuations go, TherapeuticsMD's Asset Writedowns and Impairment skyrocketed by 255.97% in 2020, and later crashed by 52.92% in 2021.
  • Yearly analysis of 3 years shows TherapeuticsMD's Asset Writedowns and Impairment stood at $1.1 million in 2020, then tumbled by 52.92% to $533,000 in 2021, then reached $1.3 million in 2024.